ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2334

Development and validation analysis of a Corrected Axial Spondyloarthritis Metrology Index

Dafne capelusnik1, Philip Gardiner2, Elena Nikiphorou3, Désirée Van Der Heijde4, Robert Landewé5, Astrid Van Tubergen6, Annelies Boonen7 and Sofia Ramiro8, 1Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, 2Altnagelvin Hospital, Londonderry, United Kingdom, 3King’s College London, London, United Kingdom, 4Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 5Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, 6Maastricht university, Maastricht, Netherlands, 7Maastricht University Medical Centre+ & Maastricht University, Maastricht, Limburg, Netherlands, 8Leiden University Medical Center, Bunde, Netherlands

Meeting: ACR Convergence 2025

Keywords: Ankylosing spondylitis (AS), Disability, Outcome measures, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2305–2337) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: The MOBILITY study, a study on spinal mobility measures in healthy individuals, showed that the Bath Ankylosing Spondylitis Metrology Index (BASMI) often overestimates spinal mobility as these measures also depend on height, sex and age, with a significant impact on older and taller individuals. To better address this, we developed a Corrected AxSpA Metrology Index (CASMI) and compared its construct validity with that of BASMI in patients with established axSpA.

Methods: Data from the MOBILITY study on spinal mobility in healthy individuals were used to develop a corrected version of the BASMI (CASMI). Age-, sex-, and height-specific normal limits were derived for each component (lateral spinal flexion -LSF-, tragus-to-wall -TTW-, intermalleolar distance -IMD-, Schobert’s test, cervical rotation -CR-) from regression models or trigonometric calculations. Components were anchored using the 50th percentile of healthy individuals (MOBILITY study, score = 0) and the 95th percentile of axSpA patients (cohort study of axSpA used, score = 10). TTW was corrected using fixed thresholds. Construct validity of several CASMI versions were compared to BASMI in an axSpA population included in the OASIS cohort. Construct validity was assessed by comparing means, minimum and maximum values, floor and ceiling effects of BASMI and CASMI, and correlations with age, height and disease outcomes (BASFI, BASDAI, ASDAS, mSASSS and number of syndesmophytes). It was hypothesized that CASMI would reduce correlations with age and height while maintaining correlations with disease measures. Differences between BASMI and CASMI in the score distributions were visualized with density plots. Known group discrimination, as part of construct validity, was tested by comparing standardized mean differences (SMD) between known groups, stratified by: i) BASFI (≤3 vs ≥6), ii) mSASSS (≥1 vs >10), and iii) syndesmophyte count (≤1 vs 5). Higher absolute SMD values indicate better discrimination, with >0.8 considered as ‘good’.

Results: Table 1 presents the formulae for the five components of BASMI, as well the formulae for the CASMI components. In the OASIS cohort, mean values for some corrected components were lower, whereas minimum values remained unchanged, and were slightly lower for CASMI. Floor effects increased in individual items (e.g., TTW: 0.5% to 52%) but remained 0% in the composite scores. Maximum values and ceiling effects increased in individual components but not in CASMI. As intended, correlation with age and height decreased in CASMI and several components, but no major changes in correlations with disease outcomes, confirming the hypotheses made (Table 2). The density plots showed that CASMI systematically yields lower scores and has a higher floor effect, suggesting better calibration and better sensitivity to capture subtle impairments in spinal mobility. Discrimination between known groups was good across all score versions and external constructs (SMD >0.80).

Conclusion: An age-, sex- and height-corrected mobility score, the CASMI, has been developed as a more personalised and truthful measure of mobility in axSpA, compared to BASMI.

Supporting image 1

Supporting image 2Figure 1. Density plots for BASMI and CASMI. CASMI represented here is CASMI_Ma which formula was adjusted using age, sex and hight correction factors derived from the regression coefficients obtained in the MOBILITY study.

Supporting image 3


Disclosures: D. capelusnik: None; P. Gardiner: AbbVie/Abbott, 1, Galapagos, 1, Gilead, 1, Pfizer, 1, UCB, 1; E. Nikiphorou: AbbVie/Abbott, 1, Alfasigma, 1, Eli Lilly, 1, 5, Fresenius, 1, Galapagos, 1, Gilead, 1, Novartis, 1, Pfizer, 1, 5, UCB, 1; D. Van Der Heijde: AbbVie, 2, Alfasigma, 2, Annals of the Rheumatic Diseases, 12, Associate editor, ArgenX, 2, Bristol Myers Squibb, 2, Eli Lilly and Company, 2, Grey-Wolf Therapeutics, 2, Imaging Rheumatology BV, 12, Director, Janssen, 2, Journal of Rheumatology, 12, Editorial board member, Novartis, 2, Pfizer, 2, RMD Open, 12, Editoral board member, Takeda, 2, UCB, 2; R. Landewé: AbbVie/Abbott, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, Janssen, 2, Joint Imaging BV, 12, Director, Novartis, 2, Pfizer, 2, Rheumatology Consultancy BV, 12, Director, UCB, 2; A. Van Tubergen: Janssen, 2, Novartis, 2, 5, 6, UCB, 5; A. Boonen: AbbVie/Abbott, 5, Alfasigma, 2, Celgene, 5, Eli Lilly, 2, Novartis, 2, Sandoz, 2, UCB, 2; S. Ramiro: AbbVie, 2, 5, Eli Lilly, 2, 5, Galapagos/Alfasigma, 2, 5, Janssen, 2, MSD, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, Sanofi, 2, 5, UCB, 2, 5.

To cite this abstract in AMA style:

capelusnik D, Gardiner P, Nikiphorou E, Van Der Heijde D, Landewé R, Van Tubergen A, Boonen A, Ramiro S. Development and validation analysis of a Corrected Axial Spondyloarthritis Metrology Index [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/development-and-validation-analysis-of-a-corrected-axial-spondyloarthritis-metrology-index/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-and-validation-analysis-of-a-corrected-axial-spondyloarthritis-metrology-index/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology